No black box warning on record for Bicalutamide

As of the latest FDA labeling reviewed, Bicalutamide (BICALUTAMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Bicalutamide medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Severe hepatic injury and fatal hepatic failure have been observed. Monitor serum transaminase levels prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment and periodically thereafter, and for symptoms or signs suggestive of hepatic dysfunction. Use bicalutamide with caution in patients with hepatic impairment. ( 5.1

No black box warning on record for Bicalutamide

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Severe hepatic injury and fatal hepatic failure have been observed. Monitor serum transaminase levels prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment and periodically thereafter, and for symptoms or signs suggestive of hepatic dysfunction. Use bicalutamide with caution in patients with hepatic impairment. ( 5.1

Bicalutamide Black Box Warning

No black box warning on record for Bicalutamide

Other warnings & precautions

Bicalutamide Black Box Warning

No black box warning on record for Bicalutamide

Other warnings & precautions